You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
高視醫療(02407.HK)預期中期利潤約1.05億至1.16億元
格隆匯 08-04 16:46

格隆匯8月4日丨高視醫療(02407.HK)公佈,相比截至2022年6月30日止六個月錄得虧損淨額約人民幣53.3百萬元,公司預期截至2023年6月30日止六個月錄得利潤淨額約人民幣104.9百萬元至人民幣115.9百萬元。

董事會認為,從虧損淨額扭轉為利潤淨額主要歸因於公司股份於2022年12月12日在香港聯合交易所有限公司上市時,公司可轉換可贖回優先股自動轉換為公司普通股。於轉換後,公司不會就優先股錄得任何公允價值虧損及匯兑虧損。因此,截至2023年6月30日止六個月,優先股公允價值虧損及外匯虧損為零,相比截至2022年6月30日止六個月則錄得約人民幣124.8百萬元。

公司預期截至2023年6月30日止六個月錄得利潤淨額約人民幣104.9百萬元至人民幣115.9百萬元,較截至2022年6月30日止六個月經調整利潤淨額(按下文定義的非國際財務報吿準則計量)約人民幣90.5百萬元,增加約15.9%至28.1%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account